Ghrelin in Patients With a Rare Disease Associated With Intellectual Disability, and Hyperphagia, and/or Overweight, and/or Obesity

Launched by UNIVERSITY HOSPITAL, TOULOUSE · Feb 23, 2021

Keywords

ClinConnect Summary

This clinical trial is investigating the levels of a hormone called ghrelin in patients with certain rare diseases that often involve intellectual disabilities and eating challenges, like Angelman Syndrome, Smith-Magenis Syndrome, Fragile X Syndrome, and Prader-Willi Syndrome. Researchers want to find out if these patients have higher ghrelin levels when they experience overeating or are overweight, similar to what is seen in Prader-Willi Syndrome.

To participate in this study, individuals must be between 3 and 50 years old and have one of the specified rare diseases along with being overweight or having a strong urge to eat. The trial is currently recruiting participants, and it's important to note that those who cannot provide informed consent or are not covered by health insurance may not be eligible. If you or someone you know qualifies, being part of this study may help us better understand how these conditions affect hunger and weight.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Patients with one of the following rare diseases associated with : Angelman syndrome, Smith-Magenis syndrome, X Fragile syndrome, rare diseases of the cerebellum, rare epilepsies, PW-like syndromes or other rare diseases with eating disorders
• • Patients aged minimum 3 years and maximum 50 years.
• • Patients with overweight (or obesity) and/or hyperphagic behavior.
• Exclusion Criteria:
• • Administrative problems: impossibility of giving parents or legal guardians informed information ; no coverage by a Social Security scheme.